Ivermectin A Potential Treatment In Covid-19, Related to Critical Illness
Qadeer et al.,
Ivermectin A Potential Treatment In Covid-19, Related to Critical Illness,
Pakistan Journal of Medical and Health Sciences, doi:10.53350/pjmhs2216824
Prospective convenience sampling study of 210 hospitalized age-matched COVID-19 patients, showing faster viral clearance with ivermectin. Baseline information per group is not provided.
This study is excluded in the after exclusion results of meta
analysis:
minimal baseline details provided.
risk of no viral clearance, 58.3% lower, RR 0.42, p < 0.001, treatment 35 of 105 (33.3%), control 84 of 105 (80.0%), NNT 2.1, mid-recovery, day 10.
|
risk of no viral clearance, 20.0% lower, RR 0.80, p < 0.001, treatment 84 of 105 (80.0%), control 105 of 105 (100.0%), NNT 5.0, day 7.
|
risk of no viral clearance, 98.6% lower, RR 0.01, p < 0.001, treatment 0 of 105 (0.0%), control 35 of 105 (33.3%), NNT 3.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Qadeer et al., 31 Aug 2022, prospective, Pakistan, peer-reviewed, median age 55.4, 6 authors, study period 1 November, 2020 - 30 May, 2021, dosage 12mg days 1-5.
Contact:
darshan.kumar@duhs.edu.pk.
Abstract: DOI: https://doi.org/10.53350/pjmhs2216824
ORIGINAL ARTICLE
Ivermectin A Potential Treatment in Covid-19, Related to Critical Illness
RASHID QADEER1, SYED MUHMMAD KASHIF2, DARSHAN KUMAR3, MADIHA MEHMMOOD4, JAWAHAR LAL5, FAIZAN6
1
Professor of Medicine, Dr.Ruth K.M Pfau Civil Hospital, Dow University Health Sciences Karachi.
Assistant Professor of Medicine, Dr.Ruth K.M Pfau Civil Hospital, Dow University Health Sciences Karachi.
Professor of Medicine, Ojha Campus, Dr.Ruth K.M Pfau Civil Hospital, Dow University Health Sciences Karachi.
4
Consultant Medicine, Dr. Ruth K.M. Pfau Civil Hospital, Dow University Health Sciences Karachi.
5
Assistant Professor, Department Medicine, SIUT Karachi.
6
PGR, Dr. Ruth K.M. Pfau Civil Hospital
Correspondence to Dr. Darshan Kumar Email: darshan.kumar@duhs.edu.pk, Cell No. +923332276994.
2
3
ABSTRACT
Aim: To evaluate the potential use of ivermectin with standard therapy among mild to moderate covid-19 illness.
Methods: This is a single-centered, prospective observational, randomized, parallel group (1:1 ratio), standard versus controlled
ivermectin study recruited 210 confirmed COVID-19 positive patients who were admitted in COVID treatment center of Dr Ruth
Kum Pafu Civil hospital Karachi, Pakistan from 1st November 2020 to 30th May 2021. Data were analyzed using SPSS version
Results: Total of 210 patients were enrolled in the study and aged matched patients were divided in two groups 105 patients
received ivermectin 6 mg twice a day for five days along with standard therapy while remaining 105 patients received standard
therapy as per local and international guidelines. Male were 140(66.7%) and female 70(33.3%); age ranges between 26 to 77
years and majority 140( 66.7%) were more than 50 years of age. Fever, dry cough and dyspnea were the major symptoms seen;
112(53.3%) patients had DM as a comorbid illness . Total of 21(20%) of 105 patients of ivermectin group had negative PCR for
COVID 19 on day seven while the other group had positive covid test in all of 105 patients . On day 10 total of 49 more patients
from ivermectin group found COVID negative along with 21 previously negative had second PCR was found negative in this way
total of 70( 66.7%) of ivermectin group had negative PCR for COVID 19 while 21(20%) patients from non ivermectin got negative
PCR for COVID 19 on day 10 .
Conclusion: Use of ivermectin with standard therapy clear the virus earlier than standard therapy in mild to moderate COVID-19
infected patients admitted in COVID treatment center of Dr Ruth Kum Pafu Civil Hospital Karachi
Keywords: Covid-19, Ivermectin, Standard Therapy .
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit